Earnings Feed
Start Free
Regulus Therapeutics Inc.·3

May 8, 8:01 PM ET

Sarissa Capital Master Fund II LP 3

3 · Regulus Therapeutics Inc. · Filed May 8, 2020

Insider Transaction Report

Form 3
Period: 2020-04-01
Regulus Therapeutics Inc.RGLS
Sarissa Capital Master Fund II LP
10% Owner
Holdings

  • Common Stock

    [F1]
    76,356

  • Warrants to Purchase Common Stock

    [F1][F2][F3]
    Exercise: $1.08From: 2020-04-01Exp: 2024-05-07→ Common Stock (23,243 underlying)

  • Warrants to Purchase Common Stock

    [F1][F2][F3]
    Exercise: $0.67From: 2020-04-01Exp: 2024-12-24→ Common Stock (53,113 underlying)

  • Class A-2 Convertible Preferred Stock

    [F2][F1][F3]
    → Common Stock (5,311 underlying)
Footnotes (3)
  • [F1]See Exhibit 99.1
  • [F2]See Exhibit 99.1
  • [F3]See Exhibit 99.1
Signature
/s/ Mark DiPaolo, Authorized Person|2020-05-08

Documents

2 files
  • 3
    doc1.xmlPrimary

    FORM 3

  • EX-99.1
    s050820a.htm

    EXPLANATION OF RESPONSES